Author

Reginster Jean-Yves

PROFESSEUR DE SANTE PUBLIQUE UNIVERSITE DE LIEGE - Cited by 98,881 - VIEILLISSEMENT MUSCULOSQUELETTIQUE

Biography

Professor Jean-Yves Reginster is the President, Chairman, the Director and Professor of Epidemiology, Public Health and Health Economics, University of Liege. He is the Head of the Center for Investigation in Bone and Articular Cartilage Metabolism, University of Liège. As Professor and Chairman, he directs the activities of Public Health Sciences, Epidemiology and Health Economics of the University of Liège, where he also heads the Centre for Investigation in Bone and Articular Cartilage Metabolism. 
Title
Cited by
Year
Management of patients at very high risk of osteoporotic fractures through sequential treatments
EM Curtis, JY Reginster, N Al-Daghri, E Biver, ML Brandi, E Cavalier, ...Aging clinical and experimental research 34 (4), 695-714, 2022202
28
2022
Role of vitamin D supplementation in the management of musculoskeletal diseases: Update from an European Society of Clinical and Economical Aspects of Osteoporosis …
T Chevalley, ML Brandi, KD Cashman, E Cavalier, NC Harvey, S Maggi, ...Aging clinical and experimental research 34 (11), 2603-2623, 2022202
18
2022
Multimodal multidisciplinary management of patients with moderate to severe pain in knee osteoarthritis: a need to meet patient expectations
N Veronese, C Cooper, O Bruyère, NM Al-Daghri, J Branco, E Cavalier, ...Drugs 82 (13), 1347-1355, 2022202
14
2022
Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies
N Veronese, G Honvo, O Bruyère, R Rizzoli, M Barbagallo, S Maggi, ...Aging Clinical and Experimental Research 35 (2), 245-252, 2023202
9
2023
Lifestyle approaches to prevent and retard sarcopenia: A narrative review
O Bruyère, JY Reginster, C BeaudartMaturitas 161, 44-48, 2022202
7
2022
Biochemical markers of musculoskeletal health and aging to be assessed in clinical trials of drugs aiming at the treatment of sarcopenia: Consensus paper from an expert group …
A Ladang, C Beaudart, JY Reginster, N Al-Daghri, O Bruyère, N Burlet, ...Calcified Tissue International 112 (2), 19-21, 2023202
7
2023
Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach
N Fuggle, N Bere, O Bruyère, MM Rosa, MC Prieto Yerro, E Dennison, ...Aging Clinical and Experimental Research 34 (9), 198-199, 2022202
5
2022
The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis
JA Kanis, EV McCloskey, NC Harvey, C Cooper, R Rizzoli, ...Osteoporosis International 34 (1), 1-9, 2023202
5
2023
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
N Fuggle, N Al-Daghri, O Bock, J Branco, O Bruyère, E Casado, ...Aging clinical and experimental research 34 (11), 262-2634, 2022202
5
2022
Sarcopenia and health‐related quality of life: A systematic review and meta‐analysis
C Beaudart, C Demonceau, JY Reginster, M Locquet, M Cesari, ...Journal of Cachexia, Sarcopenia and Muscle, 2023202
4
2023
Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative
N Veronese, L Smith, E Zigoura, M Barbagallo, LJ Dominguez, A Barone, ...Archives of Osteoporosis 17 (1), 5, 2022202
3
2022
Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment
C Beaudart, A Boonen, N Li, S Bours, S Goemaere, JY Reginster, C Roux, ...Osteoporosis international (6), 15-146, 2022202
3
2022
Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement
M Hiligsmann, N Li, C Cooper, JY Reginster, S Silverman, C Carswell, ...Osteoporosis International (8), 1641-1642, 2022202
3
2022
Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta‐analysis
K Prokopidis, P Giannos, JY Reginster, O Bruyere, M Petrovic, ...Journal of cachexia, sarcopenia and muscle 14 (2), 671-68, 20220
3
2023
Development and validation of new exercises to promote physical activity in nursing home settings
F Buckinx, L Maton, V Dalimier, A Mouton, L Lengelé, JY Reginster, ...Geriatrics 7 (5), 100, 0
2
2022
Intervention thresholds and diagnostic thresholds in the management of osteoporosis
JA Kanis, EV McCloskey, NC Harvey, C Cooper, R Rizzoli, ...Aging Clinical and Experimental Research 34 (1), 3155-3157, 0
2
2022
Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational …
S Tenti, N Veronese, S Cheleschi, I Seccafico, O Bruyère, JY Reginster, ...Aging Clinical and Experimental Research 34 (7), 1613-165, 0
2
2022
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis
S Tenti, O Bruyère, S Cheleschi, JY Reginster, N Veronese, A FioravantiTherapeutic Advances in Musculoskeletal Disease 15, 175970X31158618, 030
2
2023
Recent sarcopenia definitions—prevalence, agreement and mortality associations among men: findings from population‐based cohorts
LD Westbury, C Beaudart, O Bruyère, JA Cauley, P Cawthon, ...Journal of Cachexia, Sarcopenia and Muscle 4 (), 565-575, 2023202
1
2023
The interconnection between Covid-19, sarcopenia and lifestyle
The interconnection between Covid-9, sarcopenia and lifestyleC Demonceau, C Beaudart, JY Reginster, N Veronese, O BruyèreMaturitas 69, 56-57, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=4vY5FkAAAAAJ&hl=fr

Cited by
Citations 98881
h-index 145
i10-index 769
Recommended Journals
Open Access Journals